Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study

Overview

Journal Diabetes Spectr

Specialty Endocrinology

Date 2021 Dec 6

PMID 34866875

Authors

Timothy S Bailey

Pierre Evenou

Jasvinder Gill

Paulos Berhanu

Romain Raymond

Jodi Strong

Eugene E Wright Jr

Affiliations

Soon will be listed here.

Abstract

Background: ACHIEVE Control, a prospective, open-label, randomized, pragmatic, real-life study in insulin-naive people with type 2 diabetes (A1C 8.0-11.0%), demonstrated superiority of insulin glargine 300 units/mL (Gla-300) versus first-generation standard-of-care basal insulin (SOC-BI; glargine 100 units/mL or insulin detemir) in achieving individualized A1C targets without documented symptomatic (glucose ≤3.9 mmol/L [≤70 mg/dL] or <3.0 mmol/L [<54 mg/dL]) or severe hypoglycemia (American Diabetes Association level 3) at 6 months. Noninsulin antihyperglycemic background therapies are commonly used; however, sulfonylureas may increase hypoglycemia risk. This post hoc analysis assessed outcomes according to background therapy.

Methods: Subgroup analyses were performed per concomitant use/nonuse of sulfonylureas, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, or sodium-glucose cotransporter 2 (SGLT2) inhibitors. End points (6 and 12 months) included A1C target attainment without documented symptomatic or severe hypoglycemia, A1C target attainment, and absence of documented symptomatic or severe hypoglycemia.

Results: Odds ratios (ORs) at 12 months mostly favored Gla-300 versus SOC-BI across subgroups except in analysis of SGLT2 inhibitors, in which ORs were similar. Among sulfonylurea users, ORs at 12 months strongly favored Gla-300 versus SOC-BI for all end points, particularly A1C target achievement without documented symptomatic hypoglycemia (glucose ≤3.9 mmol/L [≤70 mg/dL]; OR 1.25, 95% CI 1.02-1.53) or severe hypoglycemia and achievement of no documented symptomatic hypoglycemia (glucose <3.0 mmol/L [<54 mg/dL]; OR 1.25, 95% CI 1.02-1.52) or severe hypoglycemia.

Conclusion: The results suggest that, in insulin-naive people with type 2 diabetes, Gla-300 is effective with a risk of hypoglycemia that is lower than or similar to that of SOC-BI regardless of background medication. Individuals receiving concomitant sulfonylureas were more likely to remain without symptomatic or severe hypoglycemia with Gla-300.

References

Mishriky B, Cummings D, Tanenberg R . The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015; 109(2):378-88. DOI: 10.1016/j.diabres.2015.05.025. View

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

Bailey T, Zhou F, Gupta R, Preblick R, Gupta V, Berhanu P . Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study. Diabetes Obes Metab. 2019; 21(7):1596-1605. PMC: 6618106. DOI: 10.1111/dom.13693. View

Roussel R, Ritzel R, Boelle-Le Corfec E, Balkau B, Rosenstock J . Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM. Diabetes Metab. 2018; 44(5):402-409. DOI: 10.1016/j.diabet.2018.02.002. View

. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2019; 43(Suppl 1):S98-S110. DOI: 10.2337/dc20-S009. View

Seaquist E, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36(5):1384-95. PMC: 3631867. DOI: 10.2337/dc12-2480. View

. 6. Glycemic Targets: . Diabetes Care. 2020; 44(Suppl 1):S73-S84. DOI: 10.2337/dc21-S006. View

Pettus J, Roussel R, Zhou F, Bosnyak Z, Westerbacka J, Berria R . Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. Diabetes Ther. 2019; 10(2):617-633. PMC: 6437256. DOI: 10.1007/s13300-019-0568-8. View

Blonde L, Meneghini L, Peng X, Boss A, Rhee K, Shaunik A . Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Ther. 2018; 9(3):1347-1358. PMC: 5984916. DOI: 10.1007/s13300-018-0413-5. View

10.

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H . Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14(9):859-64. DOI: 10.1111/j.1463-1326.2012.01627.x. View

11.

Bolli G, Riddle M, Bergenstal R, Ziemen M, Sestakauskas K, Goyeau H . New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015; 17(4):386-94. PMC: 4409854. DOI: 10.1111/dom.12438. View

12.

Perreault L, Vincent L, Neumiller J, Santos-Cavaiola T . Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions. J Am Board Fam Med. 2019; 32(3):431-447. DOI: 10.3122/jabfm.2019.03.180162. View

13.

Meneghini L, Sullivan S, Oster G, Busch R, Cali A, Dauchy A . A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. Diabetes Obes Metab. 2020; 22(11):2004-2012. PMC: 7692902. DOI: 10.1111/dom.14152. View

14.

Bolli G, Riddle M, Bergenstal R, Wardecki M, Goyeau H, Home P . Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab. 2017; 43(4):351-358. DOI: 10.1016/j.diabet.2017.04.007. View

15.

Meneghini L, Blonde L, Gill J, Dauchy A, Bacevicius A, Strong J . Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. Diabetes Obes Metab. 2020; 22(11):1995-2003. PMC: 7689721. DOI: 10.1111/dom.14116. View

16.

Douros A, DellAniello S, Yu O, Filion K, Azoulay L, Suissa S . Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018; 362:k2693. PMC: 6050517. DOI: 10.1136/bmj.k2693. View

17.

Owens D . Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opin Drug Metab Toxicol. 2016; 12(8):977-87. DOI: 10.1080/17425255.2016.1202916. View

18.

Thrasher J . Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. Am J Med. 2017; 130(6S):S4-S17. DOI: 10.1016/j.amjmed.2017.04.004. View

19.

Kalirai S, Stephenson J, Perez-Nieves M, Grabner M, Hadjiyianni I, Geremakis C . Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. Prim Care Diabetes. 2017; 12(2):155-162. DOI: 10.1016/j.pcd.2017.10.001. View

20.

Tahrani A, Barnett A, Bailey C . Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016; 12(10):566-92. DOI: 10.1038/nrendo.2016.86. View